Leerink Partnrs Has Strong Forecast for TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2026 earnings estimates for Travere Therapeutics in a report released on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of $0.63 for the year, up from their previous forecast of $0.52. The consensus estimate for Travere Therapeutics' current full-year earnings is ($3.90) per share.

A number of other research analysts also recently commented on TVTX. Canaccord Genuity Group boosted their target price on Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Evercore ISI raised their price target on Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Scotiabank raised their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, February 12th. Barclays upped their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. Finally, HC Wainwright raised their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics has an average rating of "Moderate Buy" and an average target price of $27.77.

Travere Therapeutics Stock Down 3.4 %

Shares of Travere Therapeutics stock traded down $0.81 during midday trading on Thursday, hitting $22.91. The company's stock had a trading volume of 1,466,790 shares, compared to its average volume of 1,303,585. The stock has a 50-day simple moving average of $19.22 and a 200-day simple moving average of $16.19. The firm has a market capitalization of $1.79 billion, a P/E ratio of -5.04 and a beta of 0.72. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $25.29.

Insider Activity at Travere Therapeutics

In related news, SVP William E. Rote sold 2,437 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the completion of the sale, the senior vice president now directly owns 83,170 shares in the company, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jula Inrig sold 2,066 shares of the company's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the sale, the insider now directly owns 59,883 shares of the company's stock, valued at $1,143,765.30. This represents a 3.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 218,425 shares of company stock worth $4,674,259. Company insiders own 3.75% of the company's stock.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently made changes to their positions in the stock. Rock Springs Capital Management LP lifted its stake in Travere Therapeutics by 6.2% in the 4th quarter. Rock Springs Capital Management LP now owns 4,973,649 shares of the company's stock valued at $86,641,000 after purchasing an additional 289,173 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Travere Therapeutics by 28.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company's stock valued at $41,974,000 after acquiring an additional 534,500 shares during the last quarter. Driehaus Capital Management LLC lifted its stake in shares of Travere Therapeutics by 608.1% in the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company's stock valued at $38,637,000 after acquiring an additional 1,904,733 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Travere Therapeutics by 36.7% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company's stock valued at $37,875,000 after acquiring an additional 583,836 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in Travere Therapeutics by 8.4% during the 4th quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company's stock worth $37,030,000 after acquiring an additional 165,085 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.